Paper6316147
Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia.
Heisterkamp N and 6 others. Nature, 1983. Cited by 837 papers, by iCite.
Cite this record
ConductScience Library. Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Papers, record 6316147. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6316147
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Abelson murine leukemia virus | Major topic |
| Chromosomes, Human, 21-22 and Y | Major topic |
| Chromosomes, Human, 6-12 and X | Major topic |
| Leukemia Virus, Murine | Major topic |
| Leukemia, Myeloid | Major topic |
| Oncogenes | Major topic |
| Chromosome Mapping | |
| Cloning, Molecular | |
| DNA Restriction Enzymes | |
| Gene Amplification | |
| Humans | |
| Translocation, Genetic |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| N0I-CP-75380 | NCI NIH HHS | United States | PubMed |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT02638467 | Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Failing TKIs Therapy | Background |
Source ClinicalTrials.gov
Cited by208
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 837 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42794529 | Spindle Cell Tumors with a GAB1::ABL1 Fusion-Another Member of Protein-Kinase-Related Soft Tissue Neoplasms: An (Epi)Genetic Study of Six Cases with Benign Behavior. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42794529 | PubMed |
| 42055326 | HIRA-SETDB1-H3K9me3 axis regulates chromatin architecture in leukemia cells. | J Biol Chem | 2026 | https://conductscience.org/library/papers/42055326 | PubMed |
| 41995930 | Roles of extracellular vesicles in the pathogenesis of chronic myeloid leukemia. | J Physiol Biochem | 2026 | https://conductscience.org/library/papers/41995930 | PubMed |
| 41824621 | Chronic Myeloid Leukemia: Historical Perspective, Pathophysiology, and Treatment Advances. | Acta Haematol | 2026 | https://conductscience.org/library/papers/41824621 | PubMed |
| 41824051 | [New ways in interdisciplinarity: internal medicine meets human genetics : When frequent conditions become rare and rare conditions become frequent]. | Inn Med (Heidelb) | 2026 | https://conductscience.org/library/papers/41824051 | PubMed |
| 40897850 | Targeting HDAC8 sensitizes tyrosine kinase inhibitors in the elimination of B-cell acute lymphoblastic leukemia cells through degradation of HIF-1α. | Leukemia | 2025 | https://conductscience.org/library/papers/40897850 | PubMed |
| 39831891 | scHiClassifier: a deep learning framework for cell type prediction by fusing multiple feature sets from single-cell Hi-C data. | Brief Bioinform | 2024 | https://conductscience.org/library/papers/39831891 | PubMed |
| 39652455 | BCR::ABL1-induced mitochondrial morphological alterations as a potential clinical biomarker in chronic myeloid leukemia. | Cancer Sci | 2025 | https://conductscience.org/library/papers/39652455 | PubMed |
| 39635534 | COVID-19 mitigates the response to TKIs in patients with CML via the inhibition of T-cell immunity. | Front Immunol | 2024 | https://conductscience.org/library/papers/39635534 | PubMed |
| 39104388 | Molecular biomarkers of leukemia: convergence-based drug resistance mechanisms in chronic myeloid leukemia and myeloproliferative neoplasms. | Front Pharmacol | 2024 | https://conductscience.org/library/papers/39104388 | PubMed |
| 38927048 | Advancements and Future Prospects in Molecular Targeted and siRNA Therapies for Chronic Myeloid Leukemia. | Biomolecules | 2024 | https://conductscience.org/library/papers/38927048 | PubMed |
| 38752272 | Right at your fingertips! | Haematologica | 2024 | https://conductscience.org/library/papers/38752272 | PubMed |
| 38605258 | Oral arsenic plus imatinib versus imatinib solely for newly diagnosed chronic myeloid leukemia: a randomized phase 3 trial with 5-year outcomes. | J Cancer Res Clin Oncol | 2024 | https://conductscience.org/library/papers/38605258 | PubMed |
| 38004514 | Transporter-Mediated Cellular Distribution of Tyrosine Kinase Inhibitors as a Potential Resistance Mechanism in Chronic Myeloid Leukemia. | Pharmaceutics | 2023 | https://conductscience.org/library/papers/38004514 | PubMed |
| 37778926 | Aneuploidy in human cancer: new tools and perspectives. | Trends Genet | 2023 | https://conductscience.org/library/papers/37778926 | PubMed |
| 37763211 | Prediction of Amino Acid Substitutions in ABL1 Protein Leading to Tumor Drug Resistance Based on "Structure-Property" Relationship Classification Models. | Life (Basel) | 2023 | https://conductscience.org/library/papers/37763211 | PubMed |
| 37444494 | Presence of Myeloid Mutations in Patients with Chronic Myeloid Leukemia Increases Risk of Cardiovascular Event on Tyrosine Kinase Inhibitor Treatment. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37444494 | PubMed |
| 37242605 | A Real-World Evidence-Based Study of Long-Term Tyrosine Kinase Inhibitors Dose Reduction or Discontinuation in Patients with Chronic Myeloid Leukaemia. | Pharmaceutics | 2023 | https://conductscience.org/library/papers/37242605 | PubMed |
| 37053475 | De Novo Linear Phosphorylation Site Motifs for BCR-ABL Kinase Revealed by Phospho-Proteomics in Yeast. | J Proteome Res | 2023 | https://conductscience.org/library/papers/37053475 | PubMed |
| 36882601 | Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia. | Handb Exp Pharmacol | 2023 | https://conductscience.org/library/papers/36882601 | PubMed |
Genes8
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ABL1 | 25 | PubTator's text mining | https://conductscience.org/library/genes/25 | NCBI Gene |
| BCR | 613 | PubTator's text mining | https://conductscience.org/library/genes/613 | NCBI Gene |
| BCRP8 | 100133044 | PubTator's text mining | https://conductscience.org/library/genes/100133044 | NCBI Gene |
| EXOSC2 | 23404 | PubTator's text mining | https://conductscience.org/library/genes/23404 | NCBI Gene |
| LOC107963955 | 107963955 | PubTator's text mining | https://conductscience.org/library/genes/107963955 | NCBI Gene |
| LOC107980440 | 107980440 | PubTator's text mining | https://conductscience.org/library/genes/107980440 | NCBI Gene |
| LOC108491832 | 108491832 | PubTator's text mining | https://conductscience.org/library/genes/108491832 | NCBI Gene |
| NPDC1 | 56654 | PubTator's text mining | https://conductscience.org/library/genes/56654 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/6316147
GET https://conductscience.org/api/papers/v1/6316147/cited_by?page=2